Kirsti Aas1, Sophie Dorothea Fosså2,3,4, Rune Kvåle2,5,6, Bjørn Møller2, Tor Åge Myklebust2,7, Ljiljana Vlatkovic8, Stig Müller4,9, Viktor Berge10. 1. Department of Surgery, Vestre Viken Hospital Trust, 3004, Drammen, Norway. kirstiaas@hotmail.com. 2. Cancer Registry of Norway, Ullernchausseen 64, 0379, Oslo, Norway. 3. Department of Oncology, Oslo University Hospital, Postboks 4950 Nydalen, 0424, Oslo, Norway. 4. University of Oslo, Boks 1072 Blindern, 0316, Oslo, Norway. 5. Department of Oncology, Haukeland University Hospital, Jonas Lies Vei 65, 5021, Bergen, Norway. 6. Department of Health Registries, Norwegian Institute of Public Health, Oslo, Norway. 7. Department of Research and Innovation, Møre and Romsdal Hospital Trust, Åsehaugen 1, 6026, Ålesund, Norway. 8. Department of Pathology, Oslo University Hospital, Postboks 4950 Nydalen, 0424, Oslo, Norway. 9. Department of Surgery, Akershus University Hospital, Sykehusveien 25, 1478, Lørenskog, Norway. 10. Department of Urology, Oslo University Hospital, Postboks 4950 Nydalen, 0424, Oslo, Norway.
Abstract
PURPOSE: To study the association between time from diagnosis to radical prostatectomy (RP-interval) and prostate cancer-specific mortality (PCSM), histological findings in the RP-specimen and failure after RP (RP-failure). METHODS: Patients diagnosed with non-metastatic prostate cancer (PCa) in 2001-2010 and prostatectomized within 180 days of biopsy were identified in the Cancer Registry of Norway and the Norwegian Prostate Cancer Registry. Patients were stratified according to risk groups and RP-intervals of 0-60, 61-90, 91-120 and 121-180 days. Aalen-Johansen and Kaplan-Meier methods estimated curves for PCSM, RP-failure and overall mortality. Multivariable Cox regressions and Chi-square tests were used to evaluate the impact of RP-interval on outcomes. RESULTS: In 5163 eligible patients, the median time from diagnosis to RP was 93 days (range 1-180). Risk group distribution was similar in all RP-interval groups. With almost eight years of observation, no association was found between RP-interval and PCSM in the intermediate-or high-risk groups. Increasing RP-interval did not increase the rate of adverse histological outcomes or incidence of RP-failure. CONCLUSIONS: Increasing RP-interval up to 180 days was not associated with adverse oncological outcomes at eight years follow-up. These findings should be considered when planning for prostatectomy.
PURPOSE: To study the association between time from diagnosis to radical prostatectomy (RP-interval) and prostate cancer-specific mortality (PCSM), histological findings in the RP-specimen and failure after RP (RP-failure). METHODS:Patients diagnosed with non-metastatic prostate cancer (PCa) in 2001-2010 and prostatectomized within 180 days of biopsy were identified in the Cancer Registry of Norway and the Norwegian Prostate Cancer Registry. Patients were stratified according to risk groups and RP-intervals of 0-60, 61-90, 91-120 and 121-180 days. Aalen-Johansen and Kaplan-Meier methods estimated curves for PCSM, RP-failure and overall mortality. Multivariable Cox regressions and Chi-square tests were used to evaluate the impact of RP-interval on outcomes. RESULTS: In 5163 eligible patients, the median time from diagnosis to RP was 93 days (range 1-180). Risk group distribution was similar in all RP-interval groups. With almost eight years of observation, no association was found between RP-interval and PCSM in the intermediate-or high-risk groups. Increasing RP-interval did not increase the rate of adverse histological outcomes or incidence of RP-failure. CONCLUSIONS: Increasing RP-interval up to 180 days was not associated with adverse oncological outcomes at eight years follow-up. These findings should be considered when planning for prostatectomy.
Authors: William T Berg; Matthew R Danzig; Jamie S Pak; Ruslan Korets; Arindam RoyChoudhury; Gregory Hruby; Mitchell C Benson; James M McKiernan; Ketan K Badani Journal: Prostate Date: 2015-03-21 Impact factor: 4.104
Authors: Mariana Andozia Morini; Roberto Lodeiro Muller; Paulo César Barbosa de Castro Junior; Rafael José de Souza; Eliney Ferreira Faria Journal: World J Urol Date: 2018-03-16 Impact factor: 4.226
Authors: Vincent Bourgade; Sarah J Drouin; David R Yates; Jerôme Parra; Marc-Olivier Bitker; Olivier Cussenot; Morgan Rouprêt Journal: World J Urol Date: 2013-03-02 Impact factor: 4.226
Authors: Roderick C N van den Bergh; Peter C Albertsen; Chris H Bangma; Stephen J Freedland; Markus Graefen; Andrew Vickers; Henk G van der Poel Journal: Eur Urol Date: 2013-02-22 Impact factor: 20.096
Authors: Nicolas Mottet; Joaquim Bellmunt; Michel Bolla; Erik Briers; Marcus G Cumberbatch; Maria De Santis; Nicola Fossati; Tobias Gross; Ann M Henry; Steven Joniau; Thomas B Lam; Malcolm D Mason; Vsevolod B Matveev; Paul C Moldovan; Roderick C N van den Bergh; Thomas Van den Broeck; Henk G van der Poel; Theo H van der Kwast; Olivier Rouvière; Ivo G Schoots; Thomas Wiegel; Philip Cornford Journal: Eur Urol Date: 2016-08-25 Impact factor: 20.096
Authors: Valérie Jooste; Olivier Dejardin; Véronique Bouvier; Patrick Arveux; Marc Maynadie; Guy Launoy; Anne-Marie Bouvier Journal: Int J Cancer Date: 2016-05-14 Impact factor: 7.396
Authors: R D Neal; P Tharmanathan; B France; N U Din; S Cotton; J Fallon-Ferguson; W Hamilton; A Hendry; M Hendry; R Lewis; U Macleod; E D Mitchell; M Pickett; T Rai; K Shaw; N Stuart; M L Tørring; C Wilkinson; B Williams; N Williams; J Emery Journal: Br J Cancer Date: 2015-03-31 Impact factor: 7.640
Authors: Liang G Qu; Modher Al-Shawi; Tess Howard; Nathan Papa; Cedric Poyet; Brian Kelly; A J Matthew Egan; Nathan Lawrentschuk; Damien Bolton; Gregory S Jack Journal: Int Urol Nephrol Date: 2021-10-08 Impact factor: 2.370
Authors: Nina N Harke; Christian Wagner; Robert M Hermann; Boris A Hadaschik; Jan Philipp Radtke; Alev Altay-Langguth; Stefan Aufderklamm; Christian Bach; Martina Becker-Schiebe; Andreas Blana; Frank Bruns; Stephan Buse; Stephanie E Combs; Christina L Engels; Emad Ezzibdeh; Marcel Fiedler; Laura-Anna Fischer; Mahmoud Farzat; Alexander Frismann; Matthias M Heck; Christoph Henkenberens; Marie C Roesch; Christoph Käding; Gunther Klautke; Philipp Krausewitz; Markus A Kuczyk; Conrad Leitsmann; Sebastian Lettmaier; Samy Mahjoub; Andreas Manseck; Daniel Medenwald; Andreas Meyer; Oliver Micke; Rudolf Moritz; Marcel Ott; Inga Peters; Sasa Pokupic; Daniel Porres; Felix Preisser; Kathrin Reichel; Andreas Schneider; Christian Schwentner; Sergiu Scobioala; Michael Truss; Daniel Wegener; Felix Wezel; Kay Willborn; Jörn H Witt; Andrea Wittig; Michael Wittlinger; Hendrik A Wolff; Volker Zimmermanns; Hans Christiansen Journal: PLoS One Date: 2022-06-14 Impact factor: 3.752
Authors: Valentin H Meissner; Jamila G H Strüh; Martina Kron; Lea A Liesenfeld; Stephanie Kranz; Jürgen E Gschwend; Kathleen Herkommer Journal: World J Urol Date: 2020-03-11 Impact factor: 4.226
Authors: Christopher J D Wallis; Giacomo Novara; Laura Marandino; Axel Bex; Ashish M Kamat; R Jeffrey Karnes; Todd M Morgan; Nicolas Mottet; Silke Gillessen; Alberto Bossi; Morgan Roupret; Thomas Powles; Andrea Necchi; James W F Catto; Zachary Klaassen Journal: Eur Urol Date: 2020-05-03 Impact factor: 20.096
Authors: Francisco Rodríguez-Covarrubias; Ricardo A Castillejos-Molina; Ana María Autrán-Gómez Journal: Int Braz J Urol Date: 2020-07 Impact factor: 1.541
Authors: Ekaterina Laukhtina; Reza Sari Motlagh; Keiichiro Mori; Fahad Quhal; Victor M Schuettfort; Hadi Mostafaei; Satoshi Katayama; Nico C Grossmann; Guillaume Ploussard; Pierre I Karakiewicz; Alberto Briganti; Mohammad Abufaraj; Dmitry Enikeev; Benjamin Pradere; Shahrokh F Shariat Journal: World J Urol Date: 2021-05-28 Impact factor: 4.226